EP3731837A2 - The combination comprising linagliptin and metformin - Google Patents

The combination comprising linagliptin and metformin

Info

Publication number
EP3731837A2
EP3731837A2 EP18913688.0A EP18913688A EP3731837A2 EP 3731837 A2 EP3731837 A2 EP 3731837A2 EP 18913688 A EP18913688 A EP 18913688A EP 3731837 A2 EP3731837 A2 EP 3731837A2
Authority
EP
European Patent Office
Prior art keywords
solid oral
pharmaceutical composition
oral pharmaceutical
weight
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18913688.0A
Other languages
German (de)
French (fr)
Other versions
EP3731837A4 (en
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3731837A2 publication Critical patent/EP3731837A2/en
Publication of EP3731837A4 publication Critical patent/EP3731837A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a solid oral pharmaceutical composition
  • a solid oral pharmaceutical composition comprising linagliptin, metformin and at least one pharmaceutically acceptable excipient. Further the present invention provides a method for the preparation of said composition.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Type 1 and Type 2 There are two main types of diabetes; Type 1 and Type 2:
  • Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
  • linagliptin 8-[(3R)-3-aminopiperidin-1 -yl]-7-but-2-yn-1 -yl)-3- methyl-1 -[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1 H-purine-2,6-dione and its chemical structure is shown in the Formula I.
  • Metformin is antidiabetics having an orally-administrated biguanide structure.
  • Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform.
  • Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha- glucosidase inhibitors, or insulin.
  • metformin hydrochloride is 1 ,1 -dimethylbiguanide hydrochloride, has the following chemical structure of Formula II.
  • US patent publication 201 1206766 discloses pharmaceutical composition comprising linagliptin and metformin HCI and one or more pharmaceutical excipients, and a nucleophilic and/or basic agents for stabilizing said linagliptin against degradation. Furthermore, the patent discloses use of a basic amino acid L-arginine, which may be suitable for stabilizing.
  • the present invention is aimed to obtain a stable combination formulation with synergistic effect for use in the treatment of type-2 diabetes so, this invention provides more effective treatment and at the same time, provide therapeutic effect in a shorter time.
  • the present invention is aimed to ensure good content uniformity without the addition of significant side effect.
  • Another object of the present invention is to eliminate problems and bringing additional advantages to the relevant prior art.
  • Another object of this present invention is to provide stable dosage form with desired dissolution profiles.
  • the term“combination” means that when drugs are administered together, a combined action is obtained which is higher than the individual actions of the respective drugs when they are used separately.
  • using a lower dose of each drug to be combined according to the present invention will reduce the total dosage.
  • linagliptin refers to not only linagliptin, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • the linagliptin is present as amorphous linagliptin, crystalline linagliptin having polymorphic form A, crystalline linagliptin having polymorphic form B and crystalline linagliptin having polymorphic form C or mixtures of thereof.
  • metalformin refers to not only metformin, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • combining more than one molecule in one dosage form increases the patient’s compliance.
  • this combination is increasing the patients’ quality of life, combining more than one molecule in one dosage form also reduces side effects.
  • the solid oral pharmaceutical composition comprises linagliptin and metformin.
  • a crystalline linagliptin having polymorphic form A and/or crystalline linagliptin having polymorphic form B is used form of linagliptin.
  • the amount of linagliptin in the total composition is between 0.05% and 10.0%, preferably 0.05% and 5.0% or 5.0% and 8.0% or 8.0% and 10.0% by weight.
  • a pharmaceutically acceptable polymorphs of metformin is used and the amount of metformin in the total composition is between 70.0% and 90.0%, preferably 70.0% and 75.0% or 75.0% and 81 .0% or 81 .0% and 90.0% by weight.
  • the pharmaceutically acceptable excipients are selected from disintegrants, binders, fillers, lubricants, coating agents or mixtures thereof.
  • the advantages of the present invention are even more significant, as the problem of homogeneity is even more likely to occur when two active substances are incorporated in one final dosage form, especially when two actives is used very different regarding the amount. Improved content uniformity efficiently contributes to a marked increase in bioavailability. Improved content uniformity also favors to avoid toxicity in the otherwise possible event that the amount of drug substance would be too high.
  • Linagliptin is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. Using the right disintegrant is ensured uniformity of the content.
  • Suitable disintegrants are selected from the group comprising sodium starch glycolate, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethylcellulose, alginates, gums, cross-linked calcium carboxymethylcellulose, sodium carboxymethylcellulose, ion-exchange resins or mixtures thereof.
  • the amount of disintegrant in the total composition is between 0.5% and 10.0% by weight, preferably 2.0% and 8.0% by weight, more preferably 3.0% and 6.0% by weight.
  • linagliptin are not very stable compounds.
  • amine group containing linagliptin may react with many excipients or impurities of excipients.
  • disintegrant especially sodium starch glycolate
  • the disintegrant is sodium starch glycolate, is also known as superdisintegrant, and the amount of sodium starch glycolate in the composition is between 2.0% and 8.0% by weight, preferably 3.0% and 6.0% by weight.
  • Suitable binders are selected from group comprising povidone, hydroxylpropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sugars, glucose syrups, natural gums, guar gum, tragacanth gum, pregelatinized starch, gelatins, pullulan, agar, alginate, sodium alginates, glycyrrhizin, polymetacrylates, collagen, hyaluronic acid, pectin, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, cetostearyl
  • the amount of binder in the total composition is between 0.1% and 10.0% by weight.
  • the binder is povidone.
  • povidone and sodium starch glycolate provides desired short disintegration time in composition.
  • the weight ratio of povidone of sodium starch glycolate is between 1 :5 and 5:1 , preferably between 1 :4 and 4:1.
  • Suitable fillers are selected from group comprising microcrystalline cellulose, lactose monohydrate, starch, mannitol, dibasic calcium phosphate, tribasic calcium phosphate, trehalose, isomalt, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • Suitable lubricants are selected from group comprising sodium stearyl fumarate, magnesium stearate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof.
  • Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, triacetin, glycerol triacetin, talc, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, macrogol, coloring agent or mixtures thereof.
  • PVA polyvinyl alcohol
  • PEG polyethylene glycol
  • Kollicoat® IR polyvinyl alcohol-polyethylene glycol copolymers
  • Surelease® ethylcellulose dispersions
  • PVP-VA polyvinylprolidone
  • PVP-VA polyvinylprolidone
  • Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), ponceau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • the formulation is free of basic amino acid.
  • solid oral pharmaceutical composition is in the form of tablet, capsule, pastilles, strip.
  • the solid oral pharmaceutical composition is tablet form.
  • the solid oral pharmaceutical combination is formulated as tablets comprising compressed tablets, coated or uncoated tablets, inlay tablet, multilayer tablets, inlay tablet, mini tablets, bilayer tablet, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, modified release tablets, film- coated tablets, orally disintegrating tablets, gastric disintegrating tablets, chewable tablet, dispersing tablet, lozenges.
  • the solid oral pharmaceutical combination is formulated as film coated tablet or bilayer tablet.
  • the solid oral pharmaceutical combination is tablet form.
  • Tablet comprises of at least one type of particle, for example; mini-tablet, pellets, core, agglomerates, granules, powder, liposomes, sphericles or mixtures thereof.
  • each type of particle comprises at least one active agent.
  • the solid oral pharmaceutical combination is tablet-in-tablet or core-in-tablet.
  • the solid oral pharmaceutical combination is capsule form.
  • Capsule comprises of at least one type of particle, for example; capsule, mini-tablet, pellets, agglomerates, granules, powder, liposomes, sphericles or mixtures thereof.
  • the combination is mini-capsule in capsule wherein the mini capsule comprises at least one active agent.
  • Mini-capsule is located within a capsule.
  • the combination is mini-tablets in capsule wherein a mini-tablet comprises at least one active agent.
  • Mini-tablets is located within a capsule.
  • the combination is pellet in capsule wherein pellet comprises at least one active agent.
  • Pellets are located within a capsule.
  • the combination is granule in capsule wherein granule comprises at least one active agent.
  • Granules are located within a capsule.
  • the composition comprises; a) 0.05 - 10.0% by weight of linagliptin
  • compositions of invention can be developed into solid oral dosage form comprising immediate release, extended release, sustained release, controlled release, modified release and delayed release or combination thereof.
  • Process for preparing the solid oral pharmaceutical composition comprises the following steps; a) Mixing linagliptin, metformin, microcrystalline cellulose and sodium starch glycolate b) Granulating povidone with water-ethanol mixture (70% ethanol) on a separate tank c) Mixing step (a) mixture and step (b) mixture
  • Example 1 Film coated tablet comprising linagliptin and metformin
  • Example 2 Film coated tablet comprising linagliptin and metformin
  • Example 3 Film coated tablet comprising linagliptin and metformin
  • a process for preparing the solid oral pharmaceutical composition in example 2 and example 3 comprises the following steps: a) Mixing linagliptin, metformin, microcrystalline cellulose and sodium starch glycolate b) Granulating povidone with water-ethanol mixture (70% ethanol) on a separate tank c) Mixing step (a) mixture and step (b) mixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a solid oral pharmaceutical composition comprising linagliptin, metformin and at least one pharmaceutically acceptable excipient. Further the present invention provides a method for the preparation of said composition.

Description

THE COMBINATION COMPRISING LINAGLIPTIN AND METFORMIN
Field of the Invention
The present invention relates to a solid oral pharmaceutical composition comprising linagliptin, metformin and at least one pharmaceutically acceptable excipient. Further the present invention provides a method for the preparation of said composition.
Background of the Invention
Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors. There are two main types of diabetes; Type 1 and Type 2:
Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
In Type 2 diabetes, the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin. There are two types of incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1 ) and glucose- dependent insulinotropic peptide (GIP). These hormones are naturally produced by the body in response to food intake. Their function is to help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
The chemical name of linagliptin is 8-[(3R)-3-aminopiperidin-1 -yl]-7-but-2-yn-1 -yl)-3- methyl-1 -[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1 H-purine-2,6-dione and its chemical structure is shown in the Formula I.
Formula I
Metformin is antidiabetics having an orally-administrated biguanide structure. Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform. Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha- glucosidase inhibitors, or insulin.
The chemical name of metformin hydrochloride is 1 ,1 -dimethylbiguanide hydrochloride, has the following chemical structure of Formula II.
Formula II It has been surprisingly observed that an unexpected therapeutic benefit and especially a synergistic therapeutic benefit can be obtained in the treatment of type-2 diabetes when a combination therapy comprising linagliptin and metformin are used together.
US patent publication 201 1206766 discloses pharmaceutical composition comprising linagliptin and metformin HCI and one or more pharmaceutical excipients, and a nucleophilic and/or basic agents for stabilizing said linagliptin against degradation. Furthermore, the patent discloses use of a basic amino acid L-arginine, which may be suitable for stabilizing.
In the prior art, there are combinations comprising linagliptin and metformin, the combinations uses many ways to overcome the problem of chemical degradation of free base of linagliptin, for example; using basic amino acid as stabilizer. But the process and formulation described in the prior art are complex, time consuming and costs are high.
Thus, still a need for a physically and chemically stable composition.
In the present invention, it has been found surprisingly that physically and chemically stable pharmaceutical composition comprising linagliptin and metformin that overcomes above mentioned problem without using stabilizer.
Detailed description of the Invention
The present invention is aimed to obtain a stable combination formulation with synergistic effect for use in the treatment of type-2 diabetes so, this invention provides more effective treatment and at the same time, provide therapeutic effect in a shorter time.
The present invention is aimed to ensure good content uniformity without the addition of significant side effect.
Another object of the present invention is to eliminate problems and bringing additional advantages to the relevant prior art.
Another object of this present invention is to provide stable dosage form with desired dissolution profiles. The term“combination” means that when drugs are administered together, a combined action is obtained which is higher than the individual actions of the respective drugs when they are used separately. On the other hand, using a lower dose of each drug to be combined according to the present invention will reduce the total dosage. These are advantageous in terms of patients to be treated.
The term "linagliptin" as used throughout the specification refers to not only linagliptin, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
The linagliptin is present as amorphous linagliptin, crystalline linagliptin having polymorphic form A, crystalline linagliptin having polymorphic form B and crystalline linagliptin having polymorphic form C or mixtures of thereof.
The term "metformin" as used throughout the specification refers to not only metformin, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
In this present invention, combining more than one molecule in one dosage form increases the patient’s compliance. However, while this combination is increasing the patients’ quality of life, combining more than one molecule in one dosage form also reduces side effects.
In one embodiment of the present invention, the solid oral pharmaceutical composition comprises linagliptin and metformin.
One embodiment according to this present invention, preferably crystalline linagliptin having polymorphic form A and/or crystalline linagliptin having polymorphic form B is used form of linagliptin. The amount of linagliptin in the total composition is between 0.05% and 10.0%, preferably 0.05% and 5.0% or 5.0% and 8.0% or 8.0% and 10.0% by weight. One embodiment according to this present invention, a pharmaceutically acceptable polymorphs of metformin is used and the amount of metformin in the total composition is between 70.0% and 90.0%, preferably 70.0% and 75.0% or 75.0% and 81 .0% or 81 .0% and 90.0% by weight.
In one embodiment of the present invention, the pharmaceutically acceptable excipients are selected from disintegrants, binders, fillers, lubricants, coating agents or mixtures thereof.
The advantages of the present invention are even more significant, as the problem of homogeneity is even more likely to occur when two active substances are incorporated in one final dosage form, especially when two actives is used very different regarding the amount. Improved content uniformity efficiently contributes to a marked increase in bioavailability. Improved content uniformity also favors to avoid toxicity in the otherwise possible event that the amount of drug substance would be too high.
Linagliptin is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. Using the right disintegrant is ensured uniformity of the content.
Suitable disintegrants are selected from the group comprising sodium starch glycolate, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethylcellulose, alginates, gums, cross-linked calcium carboxymethylcellulose, sodium carboxymethylcellulose, ion-exchange resins or mixtures thereof.
A sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredient should be used to form solid oral dosage forms provided herein. However, disintegrants can be mixed with other excipient to increase effective disintegration of the tablet into smaller fragments. In one embodiment of the present invention, the amount of disintegrant in the total composition is between 0.5% and 10.0% by weight, preferably 2.0% and 8.0% by weight, more preferably 3.0% and 6.0% by weight.
In general, linagliptin are not very stable compounds. Especially, in the solid dosage forms, amine group containing linagliptin may react with many excipients or impurities of excipients. In this invention, it has been surprisingly found that using disintegrant (especially sodium starch glycolate) ensures high stability of linagliptin in a solid oral dosage formulation and thus desired level of dissolution rate is provided.
In one embodiment of the present invention, the disintegrant is sodium starch glycolate, is also known as superdisintegrant, and the amount of sodium starch glycolate in the composition is between 2.0% and 8.0% by weight, preferably 3.0% and 6.0% by weight. Suitable binders are selected from group comprising povidone, hydroxylpropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sugars, glucose syrups, natural gums, guar gum, tragacanth gum, pregelatinized starch, gelatins, pullulan, agar, alginate, sodium alginates, glycyrrhizin, polymetacrylates, collagen, hyaluronic acid, pectin, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, cetostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose, polyethylene oxide, xylitol, sucrose stearate or mixtures thereof.
According to one embodiment of the present invention, the amount of binder in the total composition is between 0.1% and 10.0% by weight.
According to one embodiment of the present invention, the binder is povidone.
Furthermore, the combination of povidone and sodium starch glycolate provides desired short disintegration time in composition.
According to one embodiment of the present invention, the weight ratio of povidone of sodium starch glycolate is between 1 :5 and 5:1 , preferably between 1 :4 and 4:1.
Suitable fillers are selected from group comprising microcrystalline cellulose, lactose monohydrate, starch, mannitol, dibasic calcium phosphate, tribasic calcium phosphate, trehalose, isomalt, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
Suitable lubricants are selected from group comprising sodium stearyl fumarate, magnesium stearate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof.
Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, triacetin, glycerol triacetin, talc, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, macrogol, coloring agent or mixtures thereof.
Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), ponceau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
An embodiment of this present invention, the formulation is free of basic amino acid.
In this present invention, solid oral pharmaceutical composition is in the form of tablet, capsule, pastilles, strip.
In this present invention, the solid oral pharmaceutical composition is tablet form.
An embodiment of this present invention, the solid oral pharmaceutical combination is formulated as tablets comprising compressed tablets, coated or uncoated tablets, inlay tablet, multilayer tablets, inlay tablet, mini tablets, bilayer tablet, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, modified release tablets, film- coated tablets, orally disintegrating tablets, gastric disintegrating tablets, chewable tablet, dispersing tablet, lozenges. Preferably, the solid oral pharmaceutical combination is formulated as film coated tablet or bilayer tablet.
In this present invention, the solid oral pharmaceutical combination is tablet form. Tablet comprises of at least one type of particle, for example; mini-tablet, pellets, core, agglomerates, granules, powder, liposomes, sphericles or mixtures thereof.
According to an embodiment of this present invention, each type of particle comprises at least one active agent.
Preferably, the solid oral pharmaceutical combination is tablet-in-tablet or core-in-tablet.
In this present invention, the solid oral pharmaceutical combination is capsule form. Capsule comprises of at least one type of particle, for example; capsule, mini-tablet, pellets, agglomerates, granules, powder, liposomes, sphericles or mixtures thereof.
According to an embodiment of this present invention, the combination is mini-capsule in capsule wherein the mini capsule comprises at least one active agent. Mini-capsule is located within a capsule.
According to an embodiment of this present invention, the combination is mini-tablets in capsule wherein a mini-tablet comprises at least one active agent. Mini-tablets is located within a capsule.
According to an embodiment of this present invention, the combination is pellet in capsule wherein pellet comprises at least one active agent. Pellets are located within a capsule.
According to an embodiment of this present invention, the combination is granule in capsule wherein granule comprises at least one active agent. Granules are located within a capsule.
In this present invention, linagliptin and metformin combination are stable. The combination does not show incompatibilities, degradation problems, or extraction problems with certain excipients such as microcrystalline cellulose, sodium starch glycolate, povidone, sodium stearyl fumarate and coating agents. In one embodiment of the invention, the composition comprises; a) 0.05 - 10.0% by weight of linagliptin
b) 70.0 - 90.0% by weight of metformin
c) 1 .0 - 10.0% by weight of microcrystalline cellulose
d) 2.0 - 8.0% by weight of sodium starch glycolate
e) 0.1 - 6.0% by weight of povidone
f) 0.1 - 4.0% by weight of sodium stearyl fumarate
g) 0.1 - 6.0% by weight of coating agent
The compositions of invention can be developed into solid oral dosage form comprising immediate release, extended release, sustained release, controlled release, modified release and delayed release or combination thereof.
It has surprisingly been found that solid dosage forms of excellent uniformity and showing improved dissolution can be obtained when metformin and linagliptin are formulated together in wet granulation process. Metformin as the first pharmaceutically active ingredient is granulated together with linagliptin as second pharmaceutically active ingredient and at least one suitable pharmaceutical excipient. Wet granulation process efficiently counteracts segregation, so it can achieve good dissolution and disintegration properties.
Process for preparing the solid oral pharmaceutical composition comprises the following steps; a) Mixing linagliptin, metformin, microcrystalline cellulose and sodium starch glycolate b) Granulating povidone with water-ethanol mixture (70% ethanol) on a separate tank c) Mixing step (a) mixture and step (b) mixture
d) Drying the mixture until the humidity is less than 2.0%, then sieving the mixture e) Then, adding sodium stearyl fumarate and mixing
f) Then, pressing to form tablet
g) Coating tablets with the coating agent Example 1 : Film coated tablet comprising linagliptin and metformin
Example 2: Film coated tablet comprising linagliptin and metformin
Example 3: Film coated tablet comprising linagliptin and metformin A process for preparing the solid oral pharmaceutical composition in example 2 and example 3 comprises the following steps: a) Mixing linagliptin, metformin, microcrystalline cellulose and sodium starch glycolate b) Granulating povidone with water-ethanol mixture (70% ethanol) on a separate tank c) Mixing step (a) mixture and step (b) mixture
d) Drying the mixture until the humidity is less than 2.0%, then sieving the mixture e) Then, adding sodium stearyl fumarate and mixing
f) Then, pressing to form tablet
g) Coating tablets with the coating agent

Claims

1. A solid oral pharmaceutical composition comprising linagliptin whose total amount in the composition is 0.05% to 10.0% by weight and metformin whose total amount in the composition is 70.0% to 90.0% by weight and at least one pharmaceutically acceptable excipient.
2. The solid oral pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable excipients are selected from disintegrants, binders, fillers, lubricants, coating agents or mixtures thereof.
3. The solid oral pharmaceutical composition according to claim 2, wherein the disintegrants are sodium starch glycolate, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethylcellulose, alginates, gums, cross-linked calcium carboxymethylcellulose, sodium carboxymethylcellulose, ion-exchange resins or mixtures thereof.
4. The solid oral pharmaceutical composition according to claim 3, wherein the amount of disintegrant in the total composition is between 0.5% and 10.0% by weight.
5. The solid oral pharmaceutical composition according to claim 3 or 4, wherein the disintegrant is sodium starch glycolate.
6. The solid oral pharmaceutical composition according to claim 2, wherein the binders are selected from group comprising povidone, hydroxylpropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sugars, glucose syrups, natural gums, guar gum, tragacanth gum, pregelatinized starch, gelatins, pullulan, agar, alginate, sodium alginates, glycyrrhizin, polymetacrylates, collagen, hyaluronic acid, pectin, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, cetostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose, polyethylene oxide, xylitol, sucrose stearate or mixtures thereof.
7. The solid oral pharmaceutical composition according to claim 6, wherein the amount of binder in the total composition is between 0.1% and 10.0% by weight.
8. The solid oral pharmaceutical composition according to claim 6 or 7, wherein the binder is povidone.
9. The solid oral pharmaceutical composition according to claim 1 , wherein the formulation is free of basic amino acid.
10. The solid oral pharmaceutical composition according to any preceding claim, wherein said combination is in the form of tablet.
1 1. The solid oral pharmaceutical composition according to any preceding claim, wherein said combination is in the form of capsule.
12. The solid oral pharmaceutical composition according to any preceding claims, comprising;
0.05 - 10.0% by weight of linagliptin
70.0 - 90.0% by weight of metformin
1.0 - 10.0% by weight of microcrystalline cellulose
2.0 - 8.0% by weight of sodium starch glycolate
0.1 - 6.0% by weight of povidone
0.1 - 4.0% by weight of sodium stearyl fumarate
0.1 - 6.0% by weight of coating agent
13. A process for preparing the solid oral pharmaceutical composition according to claim 12, comprising the following steps:
a) Mixing linagliptin, metformin, microcrystalline cellulose and sodium starch glycolate
b) Granulating povidone with water-ethanol mixture on a separate tank
c) Mixing step (a) mixture and step (b) mixture
d) Drying the mixture, then sieving the mixture
e) Then, adding sodium stearyl fumarate and mixing
f) Then, pressing to form tablet
g) Coating tablets with the coating agent
EP18913688.0A 2017-12-25 2018-12-21 COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN Pending EP3731837A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/21505A TR201721505A2 (en) 2017-12-25 2017-12-25 The combination comprising linagliptin and metformin
PCT/TR2018/050857 WO2019194773A2 (en) 2017-12-25 2018-12-21 The combination comprising linagliptin and metformin

Publications (2)

Publication Number Publication Date
EP3731837A2 true EP3731837A2 (en) 2020-11-04
EP3731837A4 EP3731837A4 (en) 2021-06-30

Family

ID=67900634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18913688.0A Pending EP3731837A4 (en) 2017-12-25 2018-12-21 COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN

Country Status (3)

Country Link
EP (1) EP3731837A4 (en)
TR (1) TR201721505A2 (en)
WO (1) WO2019194773A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7689825B2 (en) * 2020-12-18 2025-06-09 日本ジェネリック株式会社 Linagliptin-containing pharmaceutical composition having excellent thermal stability
WO2022173406A1 (en) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
JP2022171507A (en) * 2021-04-30 2022-11-11 日本ジェネリック株式会社 Formulation containing linagliptin with excellent stability
WO2023002036A1 (en) * 2021-07-22 2023-01-26 Krka, D.D., Novo Mesto Process for preparing a pharmaceutical composition comprising linagliptin and metformin hydrochloride
EP4422615A4 (en) * 2021-10-28 2025-09-17 Texas A & M Univ Sys Compositions of stable metformin and similar active ingredient products with control of nitroso impurities
WO2023163510A1 (en) * 2022-02-23 2023-08-31 주식회사 제뉴원사이언스 Pharmaceutical complex formulation with controlled drug release comprising linagliptin or pharmaceutically acceptable salt thereof and metformin or pharmaceutically acceptable salt thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2014080383A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
EP2848242A1 (en) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of Linagliptin
WO2015107536A2 (en) 2013-12-09 2015-07-23 Intas Pharmaceuticals Limited Fixed dose combination comprising linagliptin and metformin hci
WO2015110962A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof

Also Published As

Publication number Publication date
EP3731837A4 (en) 2021-06-30
WO2019194773A3 (en) 2019-12-12
TR201721505A2 (en) 2019-07-22
WO2019194773A2 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
EP3731837A2 (en) The combination comprising linagliptin and metformin
EP4051246B1 (en) Bilayer tablet formulations comprising dapagliflozin and metformin
WO2019203771A2 (en) Solid oral pharmaceutical compositions comprising sitagliptin
US20190110994A1 (en) Pharmaceutical composition of dapagliflozin
WO2015110962A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof
WO2019132833A1 (en) The modified release combination comprising linagliptin and metformin
EP2468268B1 (en) Combination composition of vildagliptin and gliclazide
EP2848242A1 (en) Orally disintegrating formulations of Linagliptin
EP4161525A1 (en) The process for the preparation of a film coated tablet comprising linagliptin and metformin
EP4008317A1 (en) Solid pharmaceutical formulations of amorphous dapagliflozin
EP3976014A1 (en) A combination comprising alogliptin and metformin
CA3085455C (en) A solid oral dosage form comprising linagliptin
EP2853257A1 (en) Pharmaceutical formulations of linagliptin
WO2020013777A2 (en) Tablet formulations comprising metformin and sitagliptin
EP4079296A1 (en) A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
EP4620522A2 (en) A combination comprising vildagliptin and metformin
BR112020017056A2 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING REMOGLIFLOZINE AND AN ANTIDIABETIC AGENT
WO2018185669A1 (en) Effervescent compositions comprising saxagliptin or salt thereof
EP4171533A1 (en) A film coated tablet comprising vildagliptin and metformin hci
WO2016034710A1 (en) Pharmaceutical combinations of sitagliptin
US20250195440A1 (en) Pharmaceutical formulation comprising glucokinase activator and use thereof
WO2022173406A1 (en) A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
WO2024263133A1 (en) A monolithic tablet composition comprising linagliptin & metformin
EP4556001A1 (en) A bilayer tablet composition comprising dapagliflozin and metformin
KR20220140343A (en) Oral composite formulation comprising evogliptin and metformin and method for preparing the same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200718

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/155 20060101AFI20210526BHEP

Ipc: A61K 31/522 20060101ALI20210526BHEP

Ipc: A61K 9/20 20060101ALI20210526BHEP

Ipc: A61P 3/10 20060101ALI20210526BHEP

Ipc: A61K 9/48 20060101ALI20210526BHEP

Ipc: A61K 47/22 20060101ALI20210526BHEP

Ipc: A61K 47/32 20060101ALI20210526BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231222

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET A.S.